T umors must establish an adequate vascular network to acquire the nutrition necessary for growth and metastasis. Thus, avascular tumors that do not access a blood supply rarely grow beyond a few cubic millimeters. The latter notions provide the rationale for antiangiogenesis therapy of cancers, where the aim is to target the tumor blood supply.
1 O'Reilly et al 2 first identified the antiangiogenic factor angiostatin, representing a fragment of plasminogen. Angiostatin is a 38,000 -Da protein comprising the first four of five highly homologous 80 -aminoacid -residue -long triple -loop structures termed kringles. 2 It can efficiently inhibit the growth of a broad array of murine and human tumors established in mice, 3 and is nontoxic such that tumors can be subjected to repeated treatment cycles, without exhibiting acquired resistance to therapy. 4 Its tumor-suppressor activity may arise from its ability to inhibit the proliferation of endothelial cells by binding to the / -subunits of ATP synthase, 5 by inducing apoptotic cell death, 6 by subverting adhesion plaque formation and thereby inhibiting the migration and tube formation of endothelial cells, 7 and /or by down -regulating vascular endothelial growth factor (VEGF) expression. 8, 9 Angiostatin reduces the phosphorylation of the mitogen -activated protein kinases ERK -1 and ERK -2 in human dermal microvascular cells in response to VEGF. 10 Endothelial progenitor cells are exquisitively sensitive to the effects of angiostatin, and may be the most important target of angiostatin. 11 Antiangiogenic therapy with angiostatin requires prolonged administration of recombinant protein in vivo, which is problematic as the production and purification of angiostatin have proven to be difficult. In an alternative approach, gene therapy with viral vectors encoding angiostatin was shown to be effective in preventing the formation of tumor blood vessels, leading to increased tumor cell apoptosis, and decreased tumor growth and metastasis. 12, 13 However, viral vector -based therapies in humans are complicated by issues of safety. Regressed tumors treated with angiostatin regrow when therapy is suspended; nevertheless, prolonged tumor dormancy can be achieved by several rounds of therapy. 3, 6 Ultimately, dormant tumors could ''reawaken,'' and hence it would be preferable if angiostatin therapy could be combined with other treatment modalities that would eradicate tumors altogether. For instance, angiostatin has proven to be particularly effective when used in combination with ionizing radiation. 14, 15 Our previous studies have revealed that optimized gene transfer of several cell adhesion molecules (CAMs ) that are able to costimulate T-cell proliferation can cause the complete rejection of small (0.1 -0.2 cm in diameter ) lymphomas established in mice. 16 CAM -mediated immunotherapy is problematic in that it is ineffective against large tumors ( > 0.3 cm in diameter ), and generates weak antitumor systemic immunity. 16 In searching for ways to more effectively harness and strengthen the antitumor activity of CAM -mediated immunotherapy, we reported that immunogene therapy employing the T-cell costimulator B7.1 could be vastly improved by combining it with the antiangiogenic agents 5,6 -dimethylxanthenone -4 -acetic acid (DMXAA ) and antisense hypoxia-inducible factor 1 ( HIF -1 ). 17, 18 Combination therapy caused the complete and rapid eradication of large tumor burdens (0.4-1.0 cm in diameter ). In this paper, we have combined B7.1 immunogene therapy with angiostatin gene therapy, given that angiostatin is one of the most potent antiangiogenic factors identified. The results indicate that the latter two agents in combination are a potent cocktail, capable of eliciting enhanced antitumor activity.
MATERIALS AND METHODS

Mice and cell lines
Male C57BL /6 mice ( H -2b ), 6 -8 weeks old, were obtained from the Animal Resource Unit, Faculty of Medicine and Health Science, University of Auckland, Auckland, New Zealand. The syngeneic ( H -2b ) EL -4 thymic lymphoma cell line was purchased from the American Type Culture Collection (Rockville, MD ). It was cultured at 378C in Dulbecco's modified Eagle's medium ( DMEM; Gibco BRL, Grand Island, NY ), supplemented with 10% fetal calf serum, 50 U /mL penicillin /streptomycin, 2 mM L -glutamine, and 1 mM pyruvate.
Plasmid construction
Complementary DNA encoding the signal peptide and first four kringle regions of mouse plasminogen was polymerase chain reaction ( PCR ) -amplified from IMAGE clone 1920527 with oligonucleotide primers 5 0 -ACGAAGCTTG-GATCCATGGACCATAAGGAAGTA -3 0 and 5 0 -ACG-TCTAGACTCGAGTTATGTGGGCAATTCCACAACA-3 0 , corresponding to amino acid residues 1 -6 and 461 -466, respectively, as described previously. 19 The 1.4 -kb mouse angiostatin PCR product was subcloned into the pcDNA3 expression plasmid (Invitrogen ) (Fig 1A ) . The pCDM8 expression plasmid encoding mouse B7.1 was constructed using a full -length 1.2-kb B7.1 cDNA clone (kindly provided by Dr. P. Linsley, Bristol Myers Squibb, Seattle, WA ). The integrity of all cDNA constructs was confirmed by DNA sequence analysis.
Gene transfer of expression plasmids and monitoring antitumor activity
Purified plasmids were diluted in a solution of 5% glucose in 0.01% Triton X -100, and mixed in a ratio of 1:3 (wt /wt ) to a final concentration of 1 mg /mL with DOTAP cationic liposomes (Boehringer Mannheim, Mannheim, Germany ). As described previously, the latter is a particularly efficient transfection vehicle. 16 Tumors were established by injection of 2Â10 5 EL -4 tumor cells into the right flank of mice, and tumor growth determined by measuring two perpendicular diameters. Animals were killed when tumors reached more than 1 cm in diameter, in accordance with Animal Ethics Committee approval (University of Auckland ). Tumors reached 0.1 -0.4 cm in diameter in 14 -18 days, and were injected with 100 L of expression plasmids (100 g). For combinational treatment, reagents were delivered in a timed fashion, as described previously. 17 Thus, B7.1 cDNA was injected first, followed by two injections of angiostatin cDNA 48 and 96 hours subsequent to B7.1 gene transfer. Control tumors were injected with empty vector. Cured mice were rechallenged 3 weeks after tumor disappearance by injecting 1Â10 6 EL -4 cells subcutaneously into the opposing flank ( left flank ), followed by an even larger challenge of 1Â10 7 EL -4 cells 2 weeks later. All experiments included six mice per treatment group, and each experiment was repeated at least once.
Immunohistochemistry
Tumor cryosections ( 10 m ) prepared 2 days following gene transfer underwent overnight incubation with either an anti -B7.1 mAb ( 1G10; Pharmingen, San Diego, CA ), an antiplasminogen mAb recognizing kringles 1-3 ( CalbiochemNovabiochem, La Jolla, CA ), or a rabbit polyclonal antibody against VEGF (Ab -1; Lab Vision, Fremont, CA ). They were subsequently incubated for 30 minutes with appropriate secondary antibodies ( VECTASTAIN Universal Quick kit; Vector Laboratories, Burlingame, CA ), and developed with Sigma FAST DAB ( 3, 3 0 -diaminobenzidine tetrahydrochloride; Sigma Chemical, St. Louis, MO ) and CoCl 2 enhancer tablets (Sigma). Sections were counterstained with Mayer's hematoxylin.
Assessment of vascularity
The methodology to determine tumor vascularity has been described previously. 20 Briefly, 10-m frozen tumor sections prepared 4 days after gene transfer were immunostained with the anti -CD31 antibody MEC13.3 (Pharmingen ), as described above. Stained blood vessels were counted in five blindly chosen random fields (0.155 mm 2 ) at Â40 magnification, and the mean of the highest three counts was calculated. The concentric circles method 21, 22 was also used to assess vascularity.
In situ detection of apoptotic cells
Serial sections of 6 m thickness were prepared from excised tumors that had been frozen in liquid nitrogen, Cancer Gene Therapy, Vol 8, No 10, 2001 and stored at À 708C. TUNEL (terminal deoxynucleotidyl transferase -mediated deoxyuridine triphosphate -digoxigenin nick end labeling ) staining of sections was performed using an in situ apoptosis detection kit from Boehringer Mannheim. Briefly, frozen sections were fixed with 4% paraformaldehyde solution, permeabilized with a solution of 0.1% Triton X -100 and 0.1% sodium citrate, incubated with TUNEL reagent for 60 minutes at 378C, and examined by fluorescence microscopy. Adjacent sections were counterstained with hematoxylin and eosin. The total number of apoptotic cells in 10 randomly selected fields was counted. The apoptotic index ( AI ) was calculated as the percentage of positive staining cells, namely, AI = number of apoptotic cellsÂ100 /total number of nucleated cells.
Cell proliferation assay
To determine whether gene transfer of angiostatin affected the growth of EL -4 cells in vitro, single cell suspensions were prepared from EL -4 tumors following gene transfer of either angiostatin or empty plasmid, and seeded at 1Â10 4 cells per well on 24 -well culture plates in triplicate. Cells were grown at 378C in DMEM ( Gibco BRL ), supplemented with 10% fetal calf serum, 50 U / mL penicillin /streptomycin, 2 mM L -glutamine, and 1 mM 
Western blotting
Tumours injected 2 days earlier with angiostatin or empty expression plasmids were excised, minced with scissors, and homogenized in protein lysate buffer [ 50 mmol /L Tris, pH 7.4, 100 mol /L EDTA, 0.25 mol / L sucrose, 1% sodium dodecyl sulfate (SDS ), 1% NP40, 1 g/mL leupeptin, 1 g /mL pepstatin A, and 100 mol /L phenylmethylsulfonyl fluoride ] at 48C using a motordriven Virtus homogenizer ( Virtus, Gardiner, NY ). Tumour lysates from each group of mice were pooled, and protein content was determined. Tissue or cell debris was removed by centrifugation at 10,000Âg for 10 minutes at 48C. Protein samples ( 100 g ) were resolved on 10% polyacrylamide SDS gels under reducing conditions, and electrophoretically transferred to nitrocellulose Hybond C extra membranes (Amersham Life Science, Buckingham, England, UK ). After blocking the membranes with 5% bovine serum albumin in TTBS ( Tween 20/Tris -buffered saline 20 mmol /L Tris, 137 mmol / L NaCl, pH 7.6, containing 0.1% Tween -20 ), blots were incubated with the antiplasminogen mAb, or the Ab -1 rabbit polyclonal antibody against VEGF. They were then incubated with horseradish peroxidase -conjugated secondary antibodies, and developed by enhanced chemiluminescence ( Amersham International, Buckingham, England, UK ) and exposure to x -ray film. Band density was quantified using Scion Image software (Scion, Corporation, Frederick, MD ).
Statistical analysis
Results were expressed as mean ± SD. A Student's t test was used for evaluating statistical significance, where a value less than .05 ( P <.05 ) denotes statistical significance.
RESULTS
Gene transfer of an angiostatin expression plasmid into tumors in situ weakly retards tumor growth Small EL -4 tumors (0.1 cm in diameter ) were injected with a DNA /liposome transfection vehicle containing 100 g of angiostatin (Fig 1A ) , or B7.1 expression plasmid DNA, or control empty vector. Tumors grew rapidly in the control group, reaching 1 cm in size 14-17 days following gene transfer, whereas those treated with B7.1 plasmid completely and rapidly regressed within 1 week of gene transfer (Fig 2A ) , as described previously. 16 -18 In contrast, tumors treated with angiostatin plasmid were weakly inhibited in their growth, reaching 1 cm in size 22 -26 days following gene transfer. A repeat injection of angiostatin plasmid 48 hours after the first injection increased the therapeutic efficacy, but still failed to cause sustained tumor regression ( data not shown ). Failure of angiostatin to cause significant tumor regression was not due to poor expression of the plasmid, as immunohistochemical staining of tumor sections prepared 2 days following gene transfer, with an antibody recognizing kringles 1 -3 of plasminogen, revealed intense staining indicating that angiostatin was overexpressed in tumors ( Fig 1C ) . In contrast, sections prepared from control tumors treated with 100 g of empty vector revealed only weak endogenous levels of angiostatin (Fig 1B ) . Western blotting of homogenates of tumor cells extracted from tumors confirmed that angiostatin was overexpressed ( 3-fold ) in transfected tumors, and that it was produced at the expected size of 38 kDa ( Fig 1J) .
Vascular attack by angiostatin synergizes with B7.1 immunotherapy to eradicate large tumors
We previously reported that an attack on tumor blood vessels by either the antiangiogenic drug DMXAA, 17 or an expression vector encoding antisense HIF -1, 18 in combination with B7.1-mediated immunotherapy, overcomes tumor immune resistance and leads to the eradication of large tumors. DMXAA has the drawback that it is toxic at high therapeutic doses. Here we consider the possibility that angiostatin might be a suitable substitute for DMXAA in combination therapy. As reported previously, 17, 18 gene transfer of a B7.1 expression plasmid into large tumors ( 0.4 cm in diameter ) halved the rate of tumor growth, but was not able to induce sustained regression of EL -4 tumors ( Fig 2B ) . The failure of B7.1 therapy was not the result of poor transfection efficiency as B7.1 gene transfer led to expression of B7.1 in 90% of tumor cells ( data not shown ), in accordance with our previous results. 16, 18 The treatment of tumors 0.4 cm in diameter with angiostatin gene therapy only weakly inhibited tumor growth ( Fig 2B ) . Therapeutic efficacy against large tumors was not improved by increasing the gene dosage of angiostatin up to 250 g (Fig 2C) .
For combination therapy, tumors 0.4 cm in diameter were first injected with DNA /liposome complexes containing 100 g of B7.1, followed by two injections of angiostatin expression plasmid 48 and 96 hours later. Combined gene therapy led to complete tumor regression within 10 days, and mice remained tumor-free for 3 weeks (Fig 2B ) . Two injections of angiostatin appeared to be critical for combination therapy as only 50% of mice were cured by a single injection. To determine whether systemic antitumor immunity had been generated, cured mice were rechallenged in the opposing flank with 1Â10 6 parental tumor cells, and 2 weeks later by an even larger challenge of 1Â10 7 parental tumor cells. Such mice remained tumor-free during the 2 months of monitoring ( data not shown). In a more strenuous test of therapeutic efficacy, advanced tumors 0.6 cm in diameter were treated by combination therapy. Unfortunately, the treatment proved ineffective in eradicating very large tumors even when the gene dosage of both B7.1 and angiostatin was increased to 250 g; nevertheless, combination treatment retarded tumor growth more effectively than B7.1 monotherapy ( Fig 2D ) .
Overexpressed angiostatin reduces the density of tumor blood vessels, and increases tumor cell apoptosis independently of VEGF Gene transfer of angiostatin inhibited tumor angiogenesis, as evidenced by a statistically significant ( P < .05) reduction in 
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tumor vessel density ( Fig 1, D and E and Figure 3A ) . The median and 90th percentile distances to the nearest CD31 -labeled venules from an array of points within tumors treated with angiostatin were significantly (P < .01) longer than those in tumors treated with empty vector ( Fig 3B ) . There appeared to be a selective loss of small, presumably nascent vessels, after angiostatin therapy ( Fig 1, compare D and E ) . The introduced angiostatin had no inhibitory effect on tumoral VEGF expression, as detected by immunohistochemical staining of tumor sections with an anti -VEGFspecific antibody (Fig 1, F and G ) . Rather, VEGF expression was slightly elevated (1.5-fold ) as revealed by Western blot analysis of homogenates of tumor cells extracted from tumors (Fig 1K ) , presumably due to the increased hypoxic environment resulting from decreased blood vessel density.
The rate of tumor cell apoptosis measured by in situ labeling of fragmented DNA with terminal transferase ( TUNEL method ) was significantly (P < .001 ) increased in angiostatin -treated tumors compared to control tumors ( Fig  1, H and I and 3C ). Overexpression of angiostatin had no detectable affect on EL -4 cell growth /viability per se, as there was no significant difference (P > .05 ) in the morphological appearance or growth rate of EL -4 transfectants harvested from angiostatin -treated tumors versus those treated with empty plasmid ( Fig 3D ) .
DISCUSSION
The impetus for the present study stemmed from two previous reports, in which we demonstrated that the immune resistance of large tumors can be overcome by combining B7.1-mediated immunotherapy with a concerted attack on the tumor vasculature delivered either by the drug DMXAA, 17 or by intratumoral gene transfer of antisense HIF -1. 18 DMXAA stimulates innate immunity, resulting in the induction of a variety of bioactive molecules including TNF -, interferons, IP -10, nitric oxide, and serotonin, which leads to tumor vasculature collapse and tumor necrosis. 23 A drawback to the use of DMXAA in therapy is its unusual ''threshold'' behaviour in which only a narrow range of high, potentially toxic, doses is active. 24, 25 Antisense HIF -1 blocked tumoral expression of HIF -1, leading to down -regulation of VEGF, and tumor angiogenesis. 18 Unlike DMXAA, HIF -1-based antiangiogenic treatment cannot be readily tailored as a systemic form of therapy. Nevertheless, antisense HIF -1 therapy was instrumental in establishing that it was the antiangiogenic properties of DMXAA that were critical for the enhanced antitumor immunity achieved by combination therapy.
Because angiostatin is a potent antiangiogenic factor, we sought to determine whether it would synergize with B7.1-mediated immunotherapy. We chose angiostatin gene therapy as an initial approach because of the ease of construction of an angiostatin expression vector. Gene transfer of therapeutic proteins overcomes the problem of having to source and produce sufficient quantities of protein for therapy. This is important in the case of antiangiogenic factors, such as angiostatin, that are short -lived proteins, 2 and have to be administered continuously in large amounts for optimal and sustained benefit. 26 Gene transfer of angiostatin into tumors leads to the continuous secretion of angiostatin by the tumors themselves. However, the results obtained with angiostatin monotherapy in our study were not as spectacular as those previously obtained using recombinant angiostatin protein, 26 or viral vectors encoding angiostatin. 12 Chen et al 27 recently reported that three repeated intratumoral injections of naked angiostatin plasmids inhibited the growth ( 36% reduction in size ) of human breast cancer tumors established in nude mice. In accordance, we achieved a 25% reduction in tumor size following two repeat injections of angiostatin plasmid. Interestingly, Chen et al 27 found endostatin to be marginally more effective than angiostatin ( 49% vs 36% reduction in tumor size after three injections) when administered intratumorally, whereas systemic administration by intravenous injection was less effective ( 40% reduction in tumor size after six injections). Sacco et al 28 injected naked plasmids encoding angiostatin into the breasts of transgenic mice that spontaneously develop breast cancer. Gene delivery from an age when tumors were not clinically detectable led to strong inhibition of the growth of spontaneously developing tumors ( 90% reduction in tumor size ), but the effects were diminished when administered to detectable tumors ( 40-50% reduction in tumor size ). The degree of tumor growth inhibition appears to be directly proportional to the levels of expression of the angiostatin transgene. 29 The small EL -4 tumors may not be adequate to produce sufficient quantities of angiostatin, especially when tumor growth is impaired by the very same molecule that the tumor is expected to produce. However, such an approach provides an inherent safety mechanism, preventing the production of large amounts of angiostatin that may have deleterious effects elsewhere in the body. Repeat injections of angiostatin expression plasmid achieved better results than a single injection. Controlled ectopic expression of angiostatin at a different site such as muscle, as previously described for endostatin, 30 warrants investigation. Antiangiogenic proteins are effective at inducing tumor regression, but are not directly tumoricidal, and hence, tumor regrowth frequently occurs once treatment is suspended. The key finding of the present study is that angiostatin and B7.1 immunotherapy synergize in causing the rapid and complete rejection of large EL -4 tumors, thereby establishing that angiostatin can substitute for DMXAA. In contrast, B7.1 monotherapy was ineffective against large tumors, despite the fact that the tumors naturally expressed low levels of endogenous angiostatin. The latter can presumably be attributed to the local production of proangiogenic factors by the tumor, such as VEGF that was readily detectable, which outweigh the effects of endogenously produced angiostatin. Mice cured by combination therapy and rechallenged with live EL -4 cells remained tumor-free for at least 2 months, indicating that potent systemic antitumor immunity had been generated. As reported previously, 17, 18 timed delivery of the reagents, where B7.1 -expressed vectors were administered first, followed by angiostatin proved to be effective. angiostatin monotherapy was greater than that of control tumors treated with empty vectors. Angiostatin causes endothelial cell apoptosis, 7, 31 and as shown here inhibits neovascularization, potentially restricting the supply of tumour cell survival factors provided either by endothelial cells or by the circulation.
We considered the possibility that the effects of angiostatin might be mediated, in part, by the ability of angiostatin to down -regulate VEGF. VEGF is a potent endothelial mitogen and permeability factor, commonly expressed in tumors, which has been implicated in pathologic angiogenesis. 32 It appears to play a critical role in tumor formation, as tumor growth can be inhibited by antibody -mediated blockade of VEGF, 33 and by administration of antisense VEGF mRNA, 34 or retrovirus encoding a soluble mutant form of the VEGF receptor. 35 Tumor angiogenesis is a multistep process, where the switch to the angiogenic phenotype requires both upregulation of angiogenic stimulators and down -regulation of angiogenesis inhibitors. 36, 37 Thus, overproduction of angiogenic stimulators such as VEGF is necessary, but not sufficient for tumor vascularization. In the present study, exogenous angiostatin inhibited the formation of small, potentially nascent tumor blood vessels. The antivascular activity of angiostatin appeared to be independent of effects on VEGF expression. Rather, we found that angiostatin therapy led to a slight increase in intratumoral VEGF expression. Similarly, Ding et al 38 recently reported that intratumoral administration of endostatin caused a compensatory increase in situ of VEGF and VEGF receptor mRNA expression. Thus, tumors may antagonize antiangiogenic therapy by overproducing angiogenic factors to overcome the imposed increasing hypoxia. Angiostatin may vary in its effects on VEGF expression depending on the origin of the angiostatin molecule administered, and the type and species origin of the tumor. Thus, administration of angiostatin, purified from human plasma, inhibited VEGF expression in rat C6 and 9L gliomas, but not in human U -87 gliomas. 8 In contrast, administration of recombinant Escherichia coli -derived angiostatin (kringles 1 -3 ) almost completely prevented VEGF expression in U -87 tumors. 9 In conclusion, these results confirm that cancer immunotherapy employing B7.1 and other CAMs is of limited therapeutic use against large tumors. They emphasize that the therapeutic efficacy of CAM -mediated immunotherapy can be harnessed by combination with other treatment modalities such as antiangiogenic therapy, thereby rendering large tumors susceptible to immune attack. The combination of immunotherapy with antiangiogenic therapy warrants consideration as an approach to treat human cancers.
